Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy
The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome.
| Condition(s) | Coronary Artery Disease, Myocardial Ischaemia |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome. |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years, with at least one vessel has CT-derived FFR≤0.80 * Patients with chronic coronary syndromes * Signed written informed consent Exclusion Criteria: * The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Contrast media (Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled) * Prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) * Sinus arrhythmia, cardiogenic shock, or severe heart failure (NYHA≥III) * Inability or unwillingness to undergo CT scan or coronary angiography * Patients on hemodialysis or with severe hepatic |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Locations | Hangzhou, Zhejiang, China |
| Start date | 2024-10-10 |
| NCT ID | NCT05824520 |
| Official listing | https://clinicaltrials.gov/study/NCT05824520 |